<DOC>
	<DOCNO>NCT01390870</DOCNO>
	<brief_summary>Patient-based survey conduct evaluate driver medication adherence patient treat either 5-alpha-reductase inhibitor ( 5ARI ) therapy , alpha-blocker ( AB ) therapy , combination therapy enlarge prostate ( EP ) . Adherence EP therapy evaluate . The researcher believe majority participant report compliant therapy . The data source cross-sectional patient survey administer one time point .</brief_summary>
	<brief_title>Establishing Predictors Enlarged Prostate Treatment Adherence : Linking Symptom Improvement Adherence</brief_title>
	<detailed_description />
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>Males Aged 50 year old Residents United States Receiving prescription enlarge prostate ( EP ) treatment within 12 month prior survey initiation Patients prostate cancer health/prescription insurance patient receive medication ( ) EP PRN basis</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>Enlarged prostate , 5-alpha-reductase inhibitor , alpha-blocker , adherence</keyword>
</DOC>